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B-type natriuretic peptide trumps other
prognostic markers in patients assessed
for coronary disease
Dipak Kotecha1,2* , Marcus D. Flather3, Dan Atar4, Peter Collins5, John Pepper5, Elizabeth Jenkins6,
Christopher M. Reid2,7, David Eccleston2 and on behalf of the Alternative Risk Markers in Coronary Artery Disease
(ARM-CAD) Study
Abstract
Background: Risk prediction for patients with suspected coronary artery disease is complex due to the common
occurrence of prior cardiovascular disease and extensive risk modification in primary care. Numerous markers have
the potential to predict prognosis and guide management, but we currently lack robust ‘real-world’ evidence for
their use.
Methods: Prospective, multicentre observational study of consecutive patients referred for elective coronary
angiography. Clinicians were blinded to all risk assessments, consisting of conventional factors, radial artery
pulse wave analysis, 5-minute heart rate variability, high-sensitivity C-reactive protein and B-type natriuretic peptide
(BNP). Blinded, independent adjudication was performed for all-cause mortality and the composite of death,
myocardial infarction or stroke, analysed with Cox proportional hazards regression.
Results: Five hundred twenty-two patients were assessed with median age 66 years and 21% prior revascularization.
Median baseline left ventricular ejection fraction was 64%, and 62% had ≥ 50% stenosis on angiography. During 5.0
years median follow-up, 30% underwent percutaneous and 16% surgical revascularization. In multivariate analysis, only
age and BNP were independently associated with outcomes. The adjusted hazard ratio per log unit increase in BNP
was 2.15 for mortality (95% CI 1.45–3.19; p = 0.0001) and 1.27 for composite events (1.04–1.54; p = 0.018). Patients with
baseline BNP > 100 pg/mL had substantially higher mortality and composite events (20.9% and 32.2%) than those with
BNP ≤ 100 pg/mL (5.6% and 15.5%). BNP improved both classification and discrimination of outcomes (p≤ 0.003),
regardless of left ventricular systolic function. Conversely, high-sensitivity C-reactive protein, pulse wave analysis and
heart rate variability were unrelated to prognosis at 5 years after risk modification and treatment of coronary disease.
Conclusions: Conventional risk factors and other markers of arterial compliance, inflammation and autonomic function
have limited value for prediction of outcomes in risk-modified patients assessed for coronary disease. BNP
can independently identify patients with subtle impairment of cardiac function that might benefit from more intensive
management.
Trial registration: Clinicaltrials.gov, NCT00403351 Registered on 22 November 2006
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Introduction
The prediction of adverse cardiovascular events and
mortality is well described for patients without cardio-
vascular disease (CVD) [1, 2]. However, many patients
have prior myocardial infarction (MI) or other CVD, in-
validating standard risk scores such as Framingham. Fur-
ther, patients have often received extensive primary and
secondary prevention therapy (antiplatelet and antihy-
pertensive therapy, lipid-lowering, smoking cessation
and revascularization). Thus, conventional risk factors
are often poorly associated with coronary artery disease
(CAD) [3] or prognosis in those with established CVD
[4, 5]. This leaves limited scope for identifying patients
at high risk that might benefit from more intensive
management.
A number of different risk markers with potentially
novel mechanisms have been proposed to complement
clinical factors. B-type natriuretic peptide (BNP) assesses
cardiac strain and function [6], but is rarely considered
in clinical practice outside of heart failure assessment
despite suggestive evidence of value in CAD patients [7].
Pulse wave technologies are a surrogate for vascular
stiffness [8]; however, their value beyond standard blood
pressure is uncertain. Heart rate variability (HRV) is a
marker of autonomic function [9], but with unknown ef-
fectiveness for risk prediction [10]. High-sensitivity
C-reactive protein (hs-CRP) is an effective marker of in-
flammation, but additional risk stratification has not
been established [11].
The Alternative Risk Markers in Coronary Artery Dis-
ease (ARM-CAD) study was designed to provide an un-
biased assessment of non-invasive markers in a
‘real-world’ population. A randomised trial would not
have been ethical in this situation, so instead we
employed numerous methods to reduce potential bias.
Risk assessment was performed prior to angiography,
clinicians were blinded to results to avoid any impact on
treatment over the 5 years of follow-up, and outcomes
were independently adjudicated. Our aim was to estab-
lish the clinical value of these risk markers by assessing
their relationship with mortality and the composite of
death, MI or stroke, both early and late after planned
coronary angiography.
Methods
Patient population
Patients referred for elective coronary angiography were
recruited in three centres in Melbourne, Australia, with
consecutive enrolment 2006–2008 following written in-
formed consent. The only exclusion criteria were a pre-
cipitating acute coronary syndrome (ACS) or prior heart
transplantation. All patients were assessed prospectively,
prior to angiography, with the cardiologists blinded to
all risk assessments throughout the follow-up period.
The study was approved by local ethics committees,
conducted according to the Declaration of Helsinki, and
prospectively registered (https://clinicaltrials.gov/ct2/
show/NCT00403351).
Risk markers
Conventional risk factors were determined at patient
study visits and with blood testing, in addition to
careful review and confirmation using electronic
health records and medical notes. Information on par-
ticipants was collated with a bespoke electronic case
report system separate from any clinical databases.
Definitions on risk markers have previously been pub-
lished [3, 8, 9], and further detail is presented in
Additional file 1: Appendix 1.
Coronary angiography
Coronary angiography was performed by experienced
operators using standardised procedures. Patients were
classified as normal, minor plaque or the number of cor-
onary artery territories with a luminal stenosis ≥ 50% in
main vessels or major tributaries. To ensure consistency,
the angiographic core laboratory randomly evaluated an-
giograms during the study and at each centre, with two
experienced, blinded operators.
Outcomes
All-cause mortality and the composite of death, MI or
stroke were independently adjudicated by clinicians
blinded to patient details. Confirmation of events re-
quired documentary evidence supporting the diagnosis
(for example, a death certificate, cardiologist or neurolo-
gist diagnosis, or troponin-positive ACS). We also col-
lected detailed information about percutaneous coronary
intervention (PCI), coronary artery bypass grafting
(CABG) and other events during follow-up by reviewing
electronic and physical notes, discussion with the pa-
tients’ cardiologist or general practitioner, and yearly
telephone interviews with participants.
Statistics
Values are presented as median ± interquartile range
(IQR; 25th to 75th centiles) or percentage. Risk factor
variables were assessed by tertile for Kaplan-Meier ana-
lysis and continuously in Cox proportional hazard re-
gression. Where variables demonstrated a skewed
distribution (for example, BNP, hs-CRP, HRV power and
risk scores), these were normalised for statistical analysis
by taking the natural logarithm. We pre-specified
cut-points for a number of variables of interest: BNP
100 pg/mL, central augmentation pressure 24mmHg,
central pulse pressure 50mmHg, low-frequency HRV
250ms2 and hs-CRP 3mg/L. Group comparisons were
assessed with the Kruskal-Wallis non-parametric
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analysis of variance test, with p value adjustment for
multiple comparisons. Kaplan-Meier groups were com-
pared with the log-rank test of equality for binary vari-
ables and a log-rank trend test for tertiles.
The main multivariate Cox model consisted of age,
gender, current smoking, systolic and diastolic blood
pressure, use of renin-angiotensin-aldosterone antago-
nists, total cholesterol, statin therapy, diabetes, prior MI,
BNP, the extent of angiographic CAD, the presence of
left ventricular systolic dysfunction and revascularization
during follow-up. Additional risk markers were then
added separately. A time-varying interaction term was
also included, and results are presented as hazard ratios
(HR) with associated 95% confidence intervals (CI). We
also performed stepwise inclusion at a threshold of p <
0.2 of a much broader range of variables (including renal
function, body mass index and other medical therapy);
this had no appreciable effect on results. Interactions
were assessed with likelihood ratio testing, and the pro-
portional hazards assumption was confirmed using
Schoenfeld residuals. To understand the impact of risk
factor modification over time, analyses were also per-
formed at a 1-year landmark time point.
Harrell’s C-statistic (the area under the receiver oper-
ator curve) and Somers’ D-statistic were calculated in
the final model with and without BNP to assess its addi-
tive value. These statistics were compared using pub-
lished methods [12], with randomly generated derivation
and validation sets of equal size, stratified by age and left
ventricular systolic dysfunction. To determine the dis-
criminatory ability of baseline BNP, we calculated the
net reclassification improvement and integrated discrim-
ination improvement using logistic regression in a multi-
variate model adding BNP to conventional clinical risk
predictors (age, male gender, family history of premature
CVD, current smoking, prior MI, diabetes, blood pres-
sure ≥ 140/≥ 90mmHg or hypertensive therapy, total
cholesterol > 5.2 mmol/L [200 mg/dL], ≥ 50% stenosis on
angiography and left ventricular ejection fraction [LVEF]
< 50%) [13]. To reflect the high event proportions, pre-
dicted risk of death cut-points were a priori selected at
20%, 30% and 40%.
Post hoc analyses were performed to (1) exclude pa-
tients with atrial arrhythmias from central augmentation
pressure and HRV Kaplan-Meier plots, (2) assess the im-
pact of HRV in patients without revascularization, (3)
identify any interaction of BNP with the severity of CAD
and diastolic dysfunction, (4) exclude patients with en-
tirely normal coronary angiography or those with left
ventricular systolic dysfunction, and (5) evaluate the
pre-specified 100 pg/mL cut-point of BNP.
A two-tailed p value of < 0.05 was considered statisti-
cally significant. Analyses used complete case data as the
amount of missing data was small (no imputation
performed). Statistical analysis was performed with Stata
(version 14.2, StataCorp LP, TX, USA).
Results
The ARM-CAD longitudinal study population consists
of 526 patients recruited prior to elective coronary angi-
ography, with a median follow-up period of 5.0 years
(IQR 3.5–6.0). Follow-up data were unavailable in four
participants (0.8%, Fig. 1).
Baseline characteristics and associations
Table 1 reports the baseline demographics for the study
population, with median age 66 years (IQR 58–73) and
LVEF 64% (IQR 53–71%). Prior to angiography, 394 pa-
tients (75.5%) disclosed chest pain and 335 (64.2%) some
degree of dyspnoea. Twelve patients (2.3%) had a history
of a congestive heart failure episode. There was a broad
range of BNP values which correlated with the degree of
left ventricular systolic dysfunction, but not central pulse
pressure (Additional file 1: Appendix 2). BNP was in the
heart failure range (> 400 pg/mL) in only 5.6%.
Coronary disease, revascularization and risk reduction
The majority of patients (80%) had some degree of ath-
eroma on angiography at baseline and 62% had one or
more luminal stenoses ≥ 50%. Over the 5 years of
follow-up, 15.6% underwent CABG and 29.9% of partici-
pants had at least one PCI procedure (drug-eluting
stents used in 55%). There were similar total numbers of
revascularization procedures in those with BNP ≤ 100
pg/mL at baseline and > 100 pg/mL (p = 0.69; see Fig. 1
for breakdown and Additional file 1: Appendix 3 for
Kaplan-Meier curves). Patients were actively treated with
medical therapy even prior to angiography (Add-
itional file 1: Appendix 4) by highly involved secondary
care physicians—the mean number of hospital visits per
person was 1.3 in the first 12 months following angiog-
raphy (standard deviation 0.6 visits).
Adjudicated outcomes
Forty-seven participants (9.0%) died during follow-up.
Cardiovascular causes accounted for 23 deaths (49%), of
which 18 (38%) were due to cardiac causes and 5 (11%)
from stroke. Adjudicated death, MI or stroke occurred
in 100 participants (19.2%; 109 total events).
Kaplan-Meier univariate analysis confirmed a significant
trend across tertiles of BNP both at the 1-year landmark
point and at median 5 years of follow-up (Fig. 2a).
Hs-CRP (Fig. 2b) and central augmentation pressure
(Fig. 2c) were unrelated to outcomes at either time
point, whereas the ratio of low/high-frequency HRV
power was significant at 1 year but not at 5 years
(Fig. 2d). Conversely, both Framingham risk (Fig. 2e)
and the extent of CAD on angiography (Fig. 2f ) were
Kotecha et al. BMC Medicine           (2019) 17:72 Page 3 of 11
non-significant at 1 year, but were statistically associated
with adverse outcomes by the end of follow-up. Neither
Framingham nor SCORE had value beyond age alone
(Additional file 1: Appendix 5).
Across all multivariate models, the only individual base-
line risk markers associated with adverse outcomes were
age and BNP (Table 2 and Additional file 1: Appendix 6).
For all-cause mortality, the HR for age per 10-year incre-
ment was 2.29 (95% CI 1.51–3.48; p = 0.0001) after adjust-
ment for conventional risk factors, medical therapy, the
extent of angiographic CAD and overt left ventricular sys-
tolic dysfunction. Per log unit increase in BNP, the ad-
justed HR was 2.15 (95% CI 1.45–3.19; p = 0.0001), with
no interaction with the presence of left ventricular systolic
dysfunction (pinteraction = 0.69). Similar findings were ob-
served for death, MI or stroke. Both the Framingham and
SCORE composite risk tools were associated with adverse
outcomes in multivariate analysis, with no interaction ac-
cording to baseline cardiovascular disease (all pinteractions ≥
0.50; Table 2). A revascularization procedure during
follow-up was associated with a significant reduction in
the risk of death, with an adjusted HR of 0.45 (95% CI
0.23–0.87; p = 0.018).
Patients with baseline BNP > 100 pg/mL had substan-
tially more adverse outcomes. Deaths occurred in 24/115
(20.9%) versus 23/407 (5.7%) in patients with BNP ≤ 100
pg/mL, with an adjusted HR of 4.49 (95% CI 2.09–9.62; p
= 0.0001) and no interactions in subgroup analysis (Add-
itional file 1: Appendix 6). Death, MI or stroke occurred
in 37/115 (32.2%) with BNP > 100 pg/mL versus 63/407
(15.5%) with BNP ≤ 100 pg/mL, with an adjusted HR of
1.95 (95% CI 1.20–3.18; p = 0.007). The Kaplan-Meier sur-
vival curves are presented in Fig. 3, with clear and early
separation in patients with baseline BNP > 100 pg/mL for
both outcomes. No other cut-points were of statistical
relevance, including those for central augmentation pres-
sure, central pulse pressure, low-frequency HRV power
and hs-CRP (Additional file 1: Appendix 7). In sensitivity
analyses, BNP > 100 pg/mL had the same association with
composite outcomes after exclusion of patients with nor-
mal coronary angiography (adjusted HR 2.03, 95% CI
1.23–3.34; p = 0.006; n = 420) or exclusion of those with
Fig. 1 Flowchart for the ARM-CAD study. Includes independently adjudicated events subdivided by baseline BNP level. BNP, B-type natriuretic
peptide; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting (PCI and CABG are not mutually exclusive)
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any degree of left ventricular systolic dysfunction (adjusted
HR 2.55, 95% CI 1.40–4.61; p = 0.002; n = 423).
Discrimination value of BNP
The addition of BNP as a continuous variable increased
both Harrell’s C and Somers’ D statistics in multivariate
models (t = 4.0, p < 0.001 and t = 5.9, p < 0.001 respectively
for all-cause mortality). The C-statistic in the random val-
idation subset was 0.91 with BNP and 0.69 without. When
added to conventional risk predictors, BNP > 100 versus
≤ 100 pg/mL improved the classification of death (net
improvement in 10 cases from 47 deaths, 21.3%), with
minimal change in the classification of survivors (net
improvement in 2 cases from 475 survivors, 0.4%;
Additional file 1: Appendix 8). Both net reclassification
improvement (NRI) and integrated discrimination im-
provement (IDI) analyses were highly significant (NRI
0.281, p = 0.003; IDI 0.038, p = 0.0007). Figure 4 displays a
contour prediction map combining age and BNP to assess
the clinical risk of 5-year mortality.
A plain English summary of results for patients and
carers is presented in Additional file 2.
Table 1 Baseline characteristics
Characteristic All
N = 522
BNP ≤ 100 pg/mL
N = 407
BNP > 100 pg/mL
N = 115
p value
Median (IQR) or % Median (IQR) or % Median (IQR) or %
Age, years 66 (58–73) 64 (56–71) 70 (65–76) < 0.0001
Women, % 32.8% 33.4% 30.4% NS
Current smoker, % 16.1% 17.2% 12.2% NS
Prior myocardial infarction, % 22.2% 20.9% 27.0% NS
Prior revascularization, % 20.9% 19.9% 24.3% NS
Diabetes mellitus, % 22.0% 23.3% 17.4% NS
Left ventricular ejection fraction, %* 64 (53–71) 65 (58–72) 53 (39–67) < 0.0001
Left ventricular systolic dysfunction, % 19.0% 13.0% 40.0% < 0.0001
Body mass index, kg/m2 28 (25–31) 28 (26–31) 27 (25–31) NS
Systolic blood pressure, mmHg 140 (129–156) 139 (129–153) 145 (131–161) 0.019
Diastolic blood pressure, mmHg 79 (72–86) 79 (73–86) 77 (69–85) NS
Central augmentation pressure, mmHg† 16 (9–23) 15 (9–22) 20 (10–27) 0.003
≥ 24mmHg 23.5% 18.7% 40.7% 0.0002
Central pulse pressure, mmHg† 50 (39–63) 49 (39–61) 56 (42–73) 0.001
≥ 50mmHg 52.1% 49.1% 62.8% 0.13
Total cholesterol, mmol/L 4.5 (3.8–5.2) 4.5 (3.9–5.4) 4.1 (3.5–4.7) < 0.0001
High-density lipoprotein cholesterol, mmol/L 1.2 (1.0–1.4) 1.2 (1.0–1.4) 1.2 (1.0–1.5) NS
Estimated glomerular filtration rate, mL/min 82 (68–97) 85 (69–98) 78 (60–93) 0.002
Low-frequency heart rate variability, ms2 ‡ 211 (72–470) 213 (85–446) 191 (27–1017) NS
> 250ms2 56.5% 57.4% 52.7% NS
Total power heart rate variability, ms2 ‡ 830 (323–1954) 766 (360–1764) 1101 (198–3150) NS
High-sensitivity C-reactive protein, mg/L 1.9 (0.9–4.0) 1.9 (0.8–3.9) 2.1 (1.0–4.5) NS
> 3mg/L 32.4% 31.9% 34.2% NS
B-type natriuretic peptide, pg/mL 40 (15–90) 27 (12–53) 188 (137–413) –
> 100 pg/mL 22.0%
> 400 pg/mL 5.6%
Framingham 10-year risk, % 11 (8–20) 11 (7–20) 13 (8–20) NS
SCORE 10-year risk, % 9 (4–17) 8 (3–16) 12 (7–22) < 0.0001
NS not significant (adjusted for multiple comparisons)
*Based on the subset of patients with echocardiography prior to angiography (n = 295)
†n = 8 missing
‡Participants with a stable ECG signal over 5 min (n = 464)
n = 1 missing
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Fig. 2 Kaplan Meier curves for death, myocardial infarction or stroke. Apart from coronary angiogram results, clinicians remained blinded to all other
baseline risk markers. p values are a chi-squared log-rank test for trend performed at a landmark censoring of 1 year and at the median 5-year follow-
up. Corresponding p values for all-cause mortality alone at 5-year follow-up are a BNP p = 0.001, b hs-CRP p = 0.27, c central augmentation pressure
p = 0.38, d low/high-frequency HRV p = 0.30, e Framingham risk p = 0.026, f Angiographic coronary disease p = 0.09. *Post hoc exclusion of patients
with atrial arrhythmias at baseline or follow-up had no impact on results. †Post hoc exclusion of patients with any revascularization resulted in ptrend =
0.029 for death, MI or CVA at 5-year follow-up, and 0.18 for mortality alone. CAD, coronary artery disease
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Discussion
Our study extends the importance of BNP, a marker of
myocardial dysfunction, to include adverse cardiovascu-
lar events and death in patients with suspected CAD,
even at low elevation of BNP (suggestive of subtle car-
diac impairment). The association of BNP with progno-
sis was independent of overt left ventricular systolic
dysfunction, age and other risk factors and persisted des-
pite effective primary and secondary risk factor modifi-
cation and high rates of revascularisation over 5 years.
On the contrary, other risk markers that focus on vascu-
lar pressure and arterial compliance (PWA), inflamma-
tory responses (hs-CRP) and autonomic function (HRV)
were not independent of risk modification. The
strengths of the ARM-CAD study cohort were inclusion
of unselected and consecutive patients (with results gen-
eralisable to routine clinical practice), blinding of risk as-
sessment to clinicians, rigorous protocol-defined
assessment and follow-up, low rates of loss to follow-up
and independent adjudication of adverse outcomes.
Cardiovascular risk assessment
Risk scores like GRACE (Global Registry of Acute Cor-
onary Events) for ACS patients [14] confirm that many
of the original Framingham Heart Study risk factors may
lose relevance in patients with prevalent CVD. In our
Table 2 Multivariate analysis
All-cause mortality Death, MI or stroke
HR 95% CI p value HR 95% CI p value
Main multivariate model*
Age (per 10 years) 2.29 1.51–3.48 < 0.001 1.63 1.24–2.13 < 0.001
Male gender 1.82 0.86–3.82 0.12 1.91 1.10–3.33 0.022
Prior myocardial infarction 1.71 0.85–3.44 0.13 1.60 0.98–2.61 0.06
Diabetes 1.13 0.55–2.32 0.74 1.34 0.82–2.18 0.24
Smoking 1.39 0.63–3.10 0.41 1.39 0.78–2.47 0.26
Presence of impaired left ventricular function 1.32 0.63–2.77 0.46 1.22 0.72–2.08 0.46
Extent of angiographic CAD (per vessel with ≥ 50%) 1.03 0.77–1.39 0.84 0.90 0.72–1.13 0.38
Revascularization 0.45 0.23–0.87 0.018 1.18 0.73–1.91 0.49
Cholesterol (per 1 mmol/L) 1.09 0.79–1.49 0.60 1.14 0.91–1.42 0.26
Systolic blood pressure (per 1 mmHg) 0.99 0.98–1.01 0.36 0.99 0.98–1.01 0.36
BNP (per log unit) 2.15 1.45–3.19 < 0.001 1.27 1.04–1.54 0.018
Additional risk markers†
Pulse wave analysis
Central augmentation pressure (per 1 mmHg) 0.97 0.93–1.02 0.27 1.00 0.97–1.04 0.92
Central augmentation index (per 1%) 0.98 0.95–1.01 0.26 1.00 0.98–1.02 0.89
Central pulse pressure (per 1 mmHg) 0.98 0.93–1.04 0.59 1.00 0.96–1.04 0.88
Heart rate variability
Standard deviation of RR intervals (per log ms) 0.88 0.57–1.37 0.58 0.91 0.67–1.26 0.58
Low-frequency power (per log ms2) 0.97 0.81–1.15 0.70 0.97 0.85–1.10 0.59
Total frequency power (per log ms2) 0.95 0.78–1.15 0.58 0.95 0.82–1.09 0.45
Low to high-frequency power ratio (per log unit) 1.00 0.73–1.38 0.99 0.96 0.78–1.18 0.72
Other biomarkers
High-sensitivity C-reactive protein (per 1 mg/L) 1.11 0.85–1.46 0.43 1.00 0.84–1.20 0.98
Estimated glomerular filtration rate (per 10 mL/min) 0.94 0.81–1.09 0.40 0.99 0.90–1.08 0.76
Conventional risk scores‡
Framingham 10-year risk (per log unit) 1.69 1.19–2.41 0.004 1.64 1.00–2.68 0.049
SCORE 10-year risk (per log unit) 1.41 1.14–1.74 0.002 1.59 1.16–2.17 0.004
*Also adjusted for statin therapy, diastolic blood pressure and use of renin-angiotensin-aldosterone antagonists
†Variables separately added to the main multivariate model. Age and BNP remained significantly associated with outcomes in all models
‡Modified model that includes the risk score, prior MI, extent of angiographic CAD, impaired left ventricular function, BNP, use of renin-angiotensin-aldosterone
antagonists, use of statin therapy and revascularization on follow-up, but not the components of the risk score
pinteraction for baseline cardiovascular disease = 0.76 for all-cause mortality and 0.50 for death, MI or stroke
pinteraction for baseline cardiovascular disease = 0.96 for all-cause mortality and 0.74 for death, MI or stroke
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study, only age was independently associated with out-
comes. This highlights the need to find alternative
markers that can identify those patients at high residual
risk despite risk factor management, or in those with
existing disease.
Pulse wave analysis
Following two large outcome studies of patients free of
major CVD [15, 16], derived aortic waveforms are now
frequently used in research studies as surrogate outcome
measures. Our analysis in comorbid patients, with nearly
four times the number of events as a prior study [17],
found no relationship between the arterial waveform and
clinical outcomes. This may have been due to treatment
of underlying risk factors and use of vasoactive medica-
tions, which are known to affect central pressures [18].
Heart rate variability
Low HRV is associated with an increased risk of incident
events in those without CVD [19], can discriminate pa-
tients with a complicated course following MI [20, 21]
and is a prognostic marker in heart failure [22]. Our
prior results confirmed that reduction in HRV was an
independent predictor of the presence and severity of
angiographic CAD [9]. In the current analysis, we identi-
fied a significant relationship with crude events at the
A B
Fig. 3 Kaplan-Meier adverse event curves according to the pre-specified BNP cut-point of 100 pg/mL for a: all-cause mortality; and b: death, MI or
stroke. BNP, B-type natriuretic peptide; MI, myocardial infarction
Fig. 4 Risk contour map for adjusted predicted mortality according to age and BNP. Example: 75-year-old patient with a BNP of 25 pg/mL has a
predicted 5-year mortality of 0–5%, compared to 10–20% in a patient of the same age with a BNP of 200 pg/mL. Note that risk estimates are
based on the ARM-CAD cohort of patients with extensive modification of risk factors and concomitant disease, revascularization as required, and
highly involved secondary care physicians
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landmark 1-year point, but no association at final
follow-up, nor in multivariate analysis. This may have
been due to the lack of power (however in this case, the
clinical value is likely to be small), that HRV is not en-
tirely independent of conventional factors, or that revas-
cularisation may play a role [10]. When we excluded
patients with any prior revascularisation, we identified a
statistically significant trend for tertiles of the ratio of
low/high-frequency HRV power at 5 years. However, this
should be considered hypothesis-generating due to the
smaller sample size (n = 223) and post hoc assessment. It
is also important to note that HRV acquisition was un-
successful in 11% of our cohort, predominantly due to
rhythm abnormalities [9].
Biomarkers
hs-CRP has been extensively studied as a marker of in-
flammation, but has relatively poor ability to alter clin-
ical management [11]. In our blinded assessment of a
cohort with extensive risk management, we found no re-
lationship with long-term outcomes.
In contrast, BNP was independent of other risk factors
and was the only individual marker (aside from age) to
be associated with clinical outcomes in multivariate ana-
lysis. BNP is produced by the myocardium in response
to wall stress and acts to reduce venous return to the
heart through actions on the vascular endothelium
(smooth muscle relaxation and increased endothelial
permeability), the kidneys (stimulation of diuresis and
natriuresis) and suppression of reflex sympathetic activa-
tion [23, 24]. In patients with CAD or ACS, BNP is a
powerful predictor of death and other clinical events
[25–27], with analogous findings for NT-proBNP [28,
29]. Of interest, BNP is not associated with clinical
events in healthy patients with normal echocardiograms
and the absence of cardiovascular risk factors [30]. The
mechanism for a rise in BNP in patients with coronary
atherosclerosis but the absence of myocardial necrosis is
presumably transient left ventricular systolic dysfunc-
tion, causing myocardial stress and activation of BNP
gene transcription. This hypothesis is suggested by evi-
dence that a larger ischemic burden, and hence a greater
volume of myocardium affected, leads to a proportion-
ally higher elevation in BNP [31]. In our study, the se-
verity of CAD taking account of disturbance in usual
coronary blood flow did correlate with BNP levels, albeit
weakly (Additional file 1: Appendix 9). However, there
was no interaction with the association of BNP with ad-
verse clinical events. The impact of hibernating myocar-
dium and the nature of the ischaemic insult itself are
confounding issues, further complicated by unapparent
or transient left ventricular systolic or diastolic dysfunc-
tion [32, 33]. Like other studies, we demonstrate that
BNP is a much more sensitive marker than imaging
parameters of systolic dysfunction [29, 34] and also es-
tablish that BNP is a risk marker independent of risk
modification or incident revascularization. Our BNP
cut-point of 100 pg/mL was pre-specified, but in post
hoc analysis was demonstrated as a good inflexion point
for an increasing risk of clinical events (Additional file 1:
Appendix 10).
Our data would support the use of natriuretic peptides
in the routine assessment of not only heart failure pa-
tients, but also those under investigation for suspected
CAD, even without overt systolic dysfunction. BNP and
NT-proBNP are readily available across the world, rela-
tively cheap and can improve both classification and dis-
crimination for longer-term outcomes. At the time of
initial patient assessment, identification of patients with
subtle elevation in natriuretic peptide levels (BNP > 100
pg/mL; roughly equivalent to NT-proBNP > 300 pg/mL)
suggests a high-risk profile. In such patients, it would be
reasonable to consider further pharmacological or inter-
ventional management, although further research is re-
quired to ascertain whether pro-active, intensive therapy
would improve prognosis.
Limitations
As this study was observational, there remain potential
biases to consider, including selection for coronary angiog-
raphy (particularly in patients with known CAD or previ-
ous revascularization that are more likely to be offered
angiography). BNP levels after CABG are known to be
dependent on a number of interacting and variable factors
[35]; all analyses were therefore repeated in a cohort ex-
cluding prior CABG, and results were identical to those
presented. It is also important to note that revascularisa-
tion rates were similar, regardless of baseline (blinded)
BNP category (Additional file 1: Appendix 3). Although
clinicians were blinded to the risk assessments, we cannot
exclude the possibility that biomarkers could have been
tested in clinical practice during the follow-up period. The
lack of heart failure outcomes is a limitation of the study.
Assessment of diastolic dysfunction was not a protocol re-
quirement in this study. Post hoc analysis in patients with
available data (n = 142) showed that mitral inflow E/A ra-
tio > 2, tissue Doppler E/e′ ratio ≥ 13 or composite indices
of diastolic impairment did not interact with the associ-
ation of BNP with outcomes (pinteraction = 0.16 for death,
pinteraction = 0.72 for composite events).
Conclusions
In a real-world population, conventional risk factors and
other markers of arterial compliance, inflammation and
autonomic function had limited value for prediction of
long-term outcomes in risk-modified patients assessed
for coronary disease. BNP had a strong association with
death and cardiovascular events, even without heart
Kotecha et al. BMC Medicine           (2019) 17:72 Page 9 of 11
failure or overt ventricular dysfunction, and independent
of revascularisation. BNP > 100 pg/mL can identify pa-
tients with subtle impairment of cardiac function that
may conceptually benefit from early, targeted and indivi-
dualised management to improve prognosis.
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